[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-433723-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-433723-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","optimizing-care-for-chronic-kidney-disease-considerations-from-a-to-z","Optimizing care for chronic kidney disease: Considerations from A to Z","","Chronic kidney disease (CKD) management requires a comprehensive, multidisciplinary strategy to improve clinical outcomes. This review presents essential CKD care components from A to Z, translating evidence-based guidance into practical patient management. It covers anemia, blood pressure control, cardiovascular risk reduction, individualized glycemic targets, prevention of nephrotoxins, and systematic electrolyte and acid-base correction. Nutritional and mineral-bone disorder therapies are discussed alongside fluid and dialysis-access considerations, early complication detection, and quality-of-life focused psychosocial support.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/optimizing-care-for-chronic-kidney-disease-considerations-from-a-to-z/433723/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/optimizing-care-for-chronic-kidney-disease-considerations-from-a-to-z/433723.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the core care framework proposed for chronic kidney disease?","Question",{"text":63,"@type":64},"The review outlines an A-to-Z, comprehensive multidisciplinary framework. It covers prevention, disease-modifying strategies, complication management, and patient-centered quality-of-life support.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatments are emphasized for anemia in CKD?",{"text":68,"@type":64},"Anemia management focuses on iron supplementation, erythropoiesis-stimulating agents, and emerging therapies such as hypoxia-inducible factor prolyl hydroxylase inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the review recommend reducing cardiovascular risk in CKD patients?",{"text":72,"@type":64},"Cardiovascular protection includes blood pressure optimization using renin-angiotensin system inhibitors and calcium channel blockers, plus lipid-lowering strategies and appropriate management of atrial fibrillation-related thromboembolic risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},433723,1791197130,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","J Chin MedAssoc  \nReview ARticle  \nOptimizing care for chronic kidney disease: Considerations from A to Z  \nFan-Yu Chena,b,c, Wan-Chen Changd, Zih-Kai Kaoe, Ann Charis Tana, Szu-Yuan Lia,b, Chih-Yu Yanga,b,f,g,h, Hsuan Linb, Chih-Ching Lina,b,*  \naDivision of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cInstitute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; dDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eDepartment of Information Management, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; fInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; gCenter for Intelligent Drug Systems and Smart Bio-Devices, National Yang Ming Chiao Tung University, Hsinchu, Taiwan, ROC; hStem Cell Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC  \nAbstract  \nChronic kidney disease (CKD) management requires a comprehensive and multidisciplinary approach to optimize clinical outcomes. This review systematically outlines essential components of CKD care from A to Z, offering evidence-based guidance to enhance patient management. Anemia treatment emphasizes iron supplementation, erythropoiesis-stimulating agents, and novel hypoxia-inducible factor prolyl hydroxylase inhibitors. Achieving optimal blood pressure control through renin-angiotensin system inhibitors and calcium channel blockers reduces cardiovascular risk and delays CKD progression. Cardiovascular risk management includes statins combined with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors, along with appropriate anticoagulation therapy for atrial fibrillation. Individualized glycemic control strategies prioritize sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for their cardiovascular and renal protective effects. Vigilance in avoiding nephrotoxic agents, such as non-steroidal anti-inflammatory drugs, proton pump inhibitors, aminoglycosides, and contrast media, is essential for preventing renal injury. Rigorous management of electrolytes and acid-base disturbances, involving dietary sodium and potassium restrictions, phosphate binders, and bicarbonate supplementation, reduces CKD progression and related complications. Appropriate fluid management through dietary sodium and water restriction with individualized diuretic therapy prevents volume overload and associated cardiovascular complications. Nutritional interventions, particularly low-protein diets supplemented with ketoanalogues of amino acids, effectively delay CKD progression and control metabolic disturbances. Therapies addressing CKD-related mineral and bone disorders, including phosphate binders, vitamin D analogues, and calcimimetics, reduce the risk of vascular calcification. In addition, lipid-lowering therapies, anticoagulation therapy, optimal vascular access management for dialysis, and early detection of arrhythmias and thrombotic microangiopathy significantly enhance patient outcomes. Attention to quality of life issues, such as alleviating xerosis symptoms, promoting optimal body mass index through weight management strategies, and providing psychosocial support, further enhances patient-centered care. This comprehensive review highlights the crucial importance of a multidisciplinary approach in CKD management.  \nKeywords: Cardiovascular protection; Chronic kidney disease; Multidisciplinary care; Quality of life; Renal outcomes  \n738 [www.ejcma.org](www.ejcma.org)  \nReview Article. (2025) 88:10 J Chin MedAssoc  \nLay summary: This comprehensive review introduces an Ato Z framework for chronic kidney disease care, covering 26 essential topics ranging from anemia, blood pressure control, cardiovascular protection, and blood sugar managemen","cbCaia3WX7SXSz08","https://ap.wps.com/l/cbCaia3WX7SXSz08","pdf",805110,"English","# Abstract\n# Introduction\n## Epidemiology and burden of CKD\n## Etiologies and clinical manifestations\n## Progression to ESKD and care needs","[{\"question\":\"What is the core care framework proposed for chronic kidney disease?\",\"answer\":\"The review outlines an A-to-Z, comprehensive multidisciplinary framework. It covers prevention, disease-modifying strategies, complication management, and patient-centered quality-of-life support.\"},{\"question\":\"Which treatments are emphasized for anemia in CKD?\",\"answer\":\"Anemia management focuses on iron supplementation, erythropoiesis-stimulating agents, and emerging therapies such as hypoxia-inducible factor prolyl hydroxylase inhibitors.\"},{\"question\":\"How does the review recommend reducing cardiovascular risk in CKD patients?\",\"answer\":\"Cardiovascular protection includes blood pressure optimization using renin-angiotensin system inhibitors and calcium channel blockers, plus lipid-lowering strategies and appropriate management of atrial fibrillation-related thromboembolic risk.\"}]","Optimizing care for chronic kidney disease: Considerations from A to Z | PDF",1790665278,23]